tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lava Therapeutics doses first patient in Phase 1 LAVA-1266 study

LAVA Therapeutics (LVTX) announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia, AML, and myelodysplastic syndrome, MDS.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1